LaBrosse Nicole 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Halozyme (HALO) CFO Nicole LaBrosse Receives Award; Shares Withheld
What Happened
Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics (HALO), had restricted stock units (RSUs) and performance stock units (PSUs) vest and settle into 23,773 shares on February 16, 2026. The awards converted at $0.00 per share (no cash exercise price). To cover tax withholding obligations, 12,894 of those shares were surrendered to the issuer at an effective withholding price of $79.44 per share, totaling approximately $1,024,300. Net shares delivered to LaBrosse were 10,879.
Key Details
- Transaction date: February 16, 2026; Form 4 filed Feb 17, 2026 (timely).
- Awards settled: 5,093 + 5,329 + 13,351 = 23,773 shares (code M: exercise/conversion of derivative representing vesting).
- Shares withheld for taxes: 2,747 + 2,874 + 7,273 = 12,894 shares (code F), withheld at $79.44/share = $1,024,300 (approx).
- Net shares received: 10,879.
- Footnotes: F4 = vesting/settlement of RSUs; F5 = vesting/settlement of PSUs; F1–F3 explain shares withheld to satisfy tax withholding.
- Filing appears timely; no 10b5-1 or late-filing notation in the report.
Context
This was an award vesting/settlement event (not an open-market buy or sale). The share surrender to cover tax obligations is a routine, non-market sale mechanism (cashless/stock-withholding). Such transactions reflect compensation vesting rather than an executive-initiated sale or purchase decision.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-02-16+5,093→ 27,172 total - Tax Payment
Common Stock
[F1]2026-02-16$79.44/sh−2,747$218,222→ 24,425 total - Exercise/Conversion
Common Stock
2026-02-16+5,329→ 29,754 total - Tax Payment
Common Stock
[F2]2026-02-16$79.44/sh−2,874$228,311→ 26,880 total - Exercise/Conversion
Common Stock
2026-02-16+13,351→ 40,231 total - Tax Payment
Common Stock
[F3]2026-02-16$79.44/sh−7,273$577,767→ 32,958 total - Exercise/Conversion
Restricted Stock Units
[F4]2026-02-16−5,093→ 0 totalExercise: $0.00→ Common Stock (5,093 underlying) - Exercise/Conversion
Restricted Stock Units
[F4]2026-02-16−5,329→ 5,329 totalExercise: $0.00→ Common Stock (5,329 underlying) - Exercise/Conversion
Performance Stock Units
[F5]2026-02-16−13,351→ 0 totalExercise: $0.00→ Common Stock (13,351 underlying)
Footnotes (5)
- [F1]The reported disposition of 2,747 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- [F2]The reported disposition of 2,874 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- [F3]The reported disposition of 7,273 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- [F4]This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
- [F5]This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.